Retrospective analysis of prognostic factors for Waldenstrӧm macroglobulinemia: a multicenter cooperative study in Japan

[1]  S. Treon,et al.  MYD88 mutations can be used to identify malignant pleural effusions in Waldenström macroglobulinaemia , 2018, British journal of haematology.

[2]  M. Dimopoulos,et al.  Competing risk survival analysis in patients with symptomatic Waldenström macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapy , 2015, Haematologica.

[3]  R. Advani,et al.  Ibrutinib in previously treated Waldenström's macroglobulinemia. , 2015, The New England journal of medicine.

[4]  Takayuki Takahashi,et al.  Successful treatment of refractory cold hemagglutinemia in MYD88 L265P mutation-negative Waldenström’s macroglobulinemia with bortezomib , 2015, International Journal of Hematology.

[5]  J. Laubach,et al.  Extramedullary Waldenström macroglobulinemia , 2015, American journal of hematology.

[6]  Jianxiang Wang,et al.  Distinct characteristics and new prognostic scoring system for Chinese patients with Waldenström macroglobulinemia , 2014, Chinese medical journal.

[7]  Junshik Hong,et al.  Clinical Factors Associated with Response or Survival after Chemotherapy in Patients with Waldenström Macroglobulinemia in Korea , 2014, BioMed research international.

[8]  S. Treon,et al.  Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia. , 2014, Blood.

[9]  M. Lai,et al.  Incidence of lymphoplasmacytic lymphoma/Waldenström's macroglobulinaemia in Japan and Taiwan population‐based cancer registries, 1996–2003 , 2014, International journal of cancer.

[10]  M. Stauch,et al.  Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial , 2013, The Lancet.

[11]  E. Kimby,et al.  Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop , 2013, British journal of haematology.

[12]  Y. Kanda,et al.  Investigation of the freely available easy-to-use software ‘EZR' for medical statistics , 2012, Bone Marrow Transplantation.

[13]  N. Harris,et al.  MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. , 2012, The New England journal of medicine.

[14]  P. Morel,et al.  Risk stratification in Waldenström macroglobulinemia , 2012, Expert review of hematology.

[15]  S. Treon,et al.  Maintenance Rituximab is associated with improved clinical outcome in rituximab naïve patients with Waldenstrom Macroglobulinaemia who respond to a rituximab‐containing regimen , 2011, British journal of haematology.

[16]  M. Dimopoulos,et al.  Validation of the International Prognostic Scoring System (IPSS) for Waldenstrom's macroglobulinemia (WM) and the importance of serum lactate dehydrogenase (LDH). , 2009, Leukemia research.

[17]  P. Richardson,et al.  Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia , 2010, American journal of hematology.

[18]  R. Pfeiffer,et al.  Differential characteristics of Waldenström macroglobulinemia according to patterns of familial aggregation. , 2010, Blood.

[19]  N. Schmitz,et al.  High-dose therapy and autologous stem-cell transplantation in Waldenstrom macroglobulinemia: the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  P. Richardson,et al.  Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  D. Esseltine,et al.  Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  J. Crowley,et al.  International prognostic scoring system for Waldenstrom macroglobulinemia. , 2009, Blood.

[23]  S. Treon,et al.  Comparative outcomes following CP-R, CVP-R, and CHOP-R in Waldenström's macroglobulinemia. , 2009, Clinical lymphoma & myeloma.

[24]  K. Anderson,et al.  Lenalidomide and Rituximab in Waldenstrom's Macroglobulinemia , 2009, Clinical Cancer Research.

[25]  E. Kimby,et al.  Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  W. Klapper,et al.  The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG) , 2009, Leukemia.

[27]  M. Björkholm,et al.  Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia patients: a population-based study in Sweden. , 2008, Blood.

[28]  M. Pasmantier,et al.  Thalidomide and rituximab in Waldenstrom macroglobulinemia. , 2004, Blood.

[29]  E. Eisenhauer,et al.  Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  M. Dimopoulos,et al.  Prognostic value of serum beta2-microglobulin in patients with Waldenstrom's macroglobulinemia requiring treatment. , 2006, Clinical Lymphoma & Myeloma.

[31]  E. Kimby,et al.  Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemia. , 2006, Blood.

[32]  T. Therneau,et al.  Prognostic model for disease‐specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia , 2006, British journal of haematology.

[33]  D. Weisenburger,et al.  Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. , 2006, Blood.

[34]  C. Morton,et al.  Characterization of familial Waldenstrom's Macroglobulinemia. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  M. Dimopoulos,et al.  Survival and prognostic factors after initiation of treatment in Waldenstrom's macroglobulinemia. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[36]  M. Dimopoulos,et al.  Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. , 2003, Seminars in oncology.

[37]  P. Gobbi,et al.  Prognostic factors in symptomatic Waldenstrom's macroglobulinemia. , 2003, Seminars in oncology.

[38]  S. Montoto,et al.  Waldenström macroglobulinaemia: presenting features and outcome in a series with 217 cases , 2001, British journal of haematology.

[39]  S. Barrans,et al.  Waldenström macroglobulinemia. Development of diagnostic criteria and identification of prognostic factors. , 2001, American journal of clinical pathology.

[40]  M. Dimopoulos,et al.  Treatment of Waldenstrom's macroglobulinemia with thalidomide. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  J. Crowley,et al.  Prognostic factors and response to fludarabine therapy in patients with Waldenström macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003). , 2001, Blood.

[42]  B. Grosbois,et al.  patients with the description of a new scoring system and its validation on 253 other patients. , 2000, Blood.

[43]  P. Gobbi,et al.  Study of prognosis in Waldenström's macroglobulinemia: a proposal for a simple binary classification with clinical and investigational utility. , 1994, Blood.

[44]  A. Duhamel,et al.  Prognostic factors in Waldenström's macroglobulinemia: a report of 167 cases. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  J. Higginson,et al.  International Agency for Research on Cancer. , 1968, WHO chronicle.